Increased Circulating Polymorphonuclear Myeloid-derived Suppressor Cells Are Associated with Prognosis of Metastatic Castration-resistant Prostate Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jun 18

PMID 38887300

Authors

Takuro Kobayashi

Masayoshi Nagata

Tsuyoshi Hachiya

Haruhiko Wakita

Yoshihiro Ikehata

Keiji Takahashi

Toshiyuki China

Fumitaka Shimizu

Jun Lu

Yiming Jin

Yan Lu

Hisamitsu Ide

Shigeo Horie

Affiliations

Soon will be listed here.

Abstract

Introduction: Myeloid-derived suppressor cell (MDSC) exhibits immunosuppressive functions and affects cancer progression, but its relationship with prostate cancer remains unclear. We elucidated the association of polymorphonuclear MDSC (PMN-MDSC) and monocytic MDSC (M-MDSC) levels of the total peripheral blood mononuclear cells (PBMCs) with prostate cancer progression and evaluated their roles as prognostic indicators.

Methods: We enrolled 115 patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC, n = 62), metastatic hormone-sensitive prostate cancer (mHSPC, n = 23), and metastatic castration-resistant prostate cancer (mCRPC, n = 30). Subsequently, the proportions of MDSCs in each disease progression were compared. Log-rank tests and multivariate Cox regression analyses were performed to ascertain the associations of overall survival.

Results: The patients with mCRPC had significantly higher PMN-MDSC percentage than those with nmHSPC and mHSPC (P = 7.73 × 10 and 0.0014). Significantly elevated M-MDSC levels were observed in mCRPC patients aged <70 years (P = 0.016) and with a body mass index (BMI) <25 kg/m (P = 0.043). The high PMN-MDSC group had notably shorter median survival duration (159 days) than the low PMN-MDSC group (768 days, log-rank P = 0.018). In the multivariate analysis including age, BMI, and MDSC subset, PMN-MDSC was significantly associated with prognosis (hazard ratios, 3.48; 95% confidence interval: 1.05-11.56, P = 0.042).

Discussion: PMN-MDSC levels are significantly associated with mCRPC prognosis. Additionally, we highlight the remarkable associations of age and BMI with M-MDSC levels in mCRPC, offering novel insights into MDSC dynamics in prostate cancer progression.

Citing Articles

The heterogeneity of neutrophils in cancer and its implication for therapeutic targeting.

Eruslanov E, Nefedova Y, Gabrilovich D Nat Immunol. 2025; 26(1):17-28.

PMID: 39747431 DOI: 10.1038/s41590-024-02029-y.

References

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-57. PMC: 3641696. DOI: 10.1200/JCO.2012.43.1882. View

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C . Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18(8):1254-61. DOI: 10.1038/nm.2883. View

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T . EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016; 71(4):630-642. DOI: 10.1016/j.eururo.2016.08.002. View

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A . Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008; 111(8):4233-44. DOI: 10.1182/blood-2007-07-099226. View

Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside T . Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012; 381(1-2):14-22. PMC: 3385927. DOI: 10.1016/j.jim.2012.04.004. View

Santegoets S, Stam A, Lougheed S, Gall H, Jooss K, Sacks N . Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. 2015; 2:31. PMC: 4507359. DOI: 10.1186/s40425-014-0031-3. View

Harris W, Mostaghel E, Nelson P, Montgomery B . Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009; 6(2):76-85. PMC: 2981403. DOI: 10.1038/ncpuro1296. View

Haverkamp J, Smith A, Weinlich R, Dillon C, Qualls J, Neale G . Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014; 41(6):947-59. PMC: 4272664. DOI: 10.1016/j.immuni.2014.10.020. View

Alves A, Ishimura M, de Oliveira Duarte Y, Bueno V . Parameters of the Immune System and Vitamin D Levels in Old Individuals. Front Immunol. 2018; 9:1122. PMC: 5992391. DOI: 10.3389/fimmu.2018.01122. View

10.

James N, Tannock I, Ndow J, Feng F, Gillessen S, Ali S . The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024; 403(10437):1683-1722. PMC: 7617369. DOI: 10.1016/S0140-6736(24)00651-2. View

11.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2017; 162(2):454. DOI: 10.1016/j.cell.2015.06.053. View

12.

Rybtsova N, Berezina T, Rybtsov S . Molecular Markers of Blood Cell Populations Can Help Estimate Aging of the Immune System. Int J Mol Sci. 2023; 24(6). PMC: 10055688. DOI: 10.3390/ijms24065708. View

13.

Raber P, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez M . Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2013; 134(12):2853-64. PMC: 3980009. DOI: 10.1002/ijc.28622. View

14.

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

15.

Friedrich K, Sommer M, Strobel S, Thrum S, Bluher M, Wagner U . Perturbation of the Monocyte Compartment in Human Obesity. Front Immunol. 2019; 10:1874. PMC: 6694869. DOI: 10.3389/fimmu.2019.01874. View

16.

Yang Z, Guo J, Weng L, Tang W, Jin S, Ma W . Myeloid-derived suppressor cells-new and exciting players in lung cancer. J Hematol Oncol. 2020; 13(1):10. PMC: 6995114. DOI: 10.1186/s13045-020-0843-1. View

17.

Verschoor C, Johnstone J, Millar J, Dorrington M, Habibagahi M, Lelic A . Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol. 2013; 93(4):633-7. PMC: 3701116. DOI: 10.1189/jlb.0912461. View

18.

Idorn M, Kollgaard T, Kongsted P, Sengelov L, Straten P . Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014; 63(11):1177-87. PMC: 11028426. DOI: 10.1007/s00262-014-1591-2. View

19.

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View